Verzenios ® ▼ (abemaciclib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: (England, Scotland, Wales) or (Northern Ireland).

Is Verzenios® ▼ (abemaciclib) dose adjustment required for patients with renal impairment?

No abemaciclib dose adjustment is required for patients with mild or moderate renal impairment. We have no data in patients with severe impairment or on dialysis.


No Data in Patients with Severe Renal Impairment, End Stage Renal Disease or Dialysis

While abemaciclib is not contraindicated, we have no data in patients

  • with severe renal impairment (creatinine clearance estimated by Cockroft-Gault <30 mL/min)
  • with end stage renal disease, or
  • on dialysis.1,2

Administer abemaciclib with caution in patients with severe renal impairment and closely monitor for signs of toxicity.1


1Verzenios [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: 28 October 2021

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request